Share on StockTwits

Shares of Kindred Biosciences (NYSE:KIN) traded up 3.7% on Thursday following insider buying activity, American Banking and Market News reports. The stock traded as high as $11.08 and last traded at $11.02, with a volume of 269,034 shares traded. The stock had previously closed at $10.63.

Specifically, Director Ernest Mario acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were purchased at an average price of $10.55 per share, with a total value of $105,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at BMO Capital Markets cut their price target on shares of Kindred Biosciences from $30.00 to $19.00 in a research note on Thursday, August 21st. Separately, analysts at Leerink Swann cut their price target on shares of Kindred Biosciences from $29.00 to $11.25 in a research note on Thursday, August 21st. Finally, analysts at Roth Capital cut their price target on shares of Kindred Biosciences to $11.50 in a research note on Thursday, August 21st. Two research analysts have rated the stock with a buy rating, Kindred Biosciences has an average rating of “Buy” and a consensus target price of $13.92.

The stock’s 50-day moving average is $14.23 and its 200-day moving average is $17.61. The company’s market cap is $217.8 million.

Kindred Biosciences (NYSE:KIN) last announced its earnings results on Wednesday, August 13th. The company reported ($0.42) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.35) by $0.07. On average, analysts predict that Kindred Biosciences will post $-1.75 earnings per share for the current fiscal year.

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company focused on pets.

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.